Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity.

Hutchinson PE, Halsall JA, Popovici S, Papadogeorgakis E, Osborne JE, Powley IR, Dasari D, Saldanha G, Pringle JH.

Melanoma Res. 2018 Oct;28(5):410-422. doi: 10.1097/CMR.0000000000000475.

PMID:
30004989
2.

Short stretches of rare codons regulate translation of the transcription factor ZEB2 in cancer cells.

Wan Makhtar WR, Browne G, Karountzos A, Stevens C, Alghamdi Y, Bottrill AR, Mistry S, Smith E, Bushel M, Pringle JH, Sayan AE, Tulchinsky E.

Oncogene. 2017 Nov 23;36(47):6640-6648. doi: 10.1038/onc.2017.273. Epub 2017 Aug 7.

3.

Ex Vivo Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy.

Karekla E, Liao WJ, Sharp B, Pugh J, Reid H, Quesne JL, Moore D, Pritchard C, MacFarlane M, Pringle JH.

Cancer Res. 2017 Apr 15;77(8):2029-2039. doi: 10.1158/0008-5472.CAN-16-1121. Epub 2017 Feb 15.

4.

A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis.

Romaine ST, Wells-Jordan P, de Haro T, Dave-Thakrar A, North J, Pringle JH, Saldanha G.

Melanoma Res. 2016 Dec;26(6):580-587.

PMID:
27603549
5.

5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.

Saldanha G, Joshi K, Lawes K, Bamford M, Moosa F, Teo KW, Pringle JH.

Mod Pathol. 2017 Jan;30(1):60-68. doi: 10.1038/modpathol.2016.159. Epub 2016 Oct 7.

6.

microRNA-10b is a prognostic biomarker for melanoma.

Saldanha G, Elshaw S, Sachs P, Alharbi H, Shah P, Jothi A, Pringle JH.

Mod Pathol. 2016 Feb;29(2):112-21. doi: 10.1038/modpathol.2015.149. Epub 2016 Jan 8.

7.

MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma.

Saldanha G, Potter L, Lee YS, Watson S, Shendge P, Pringle JH.

Melanoma Res. 2016 Feb;26(1):21-8. doi: 10.1097/CMR.0000000000000216.

PMID:
26731559
8.

Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.

Pal RP, Kockelbergh RC, Pringle JH, Cresswell L, Hew R, Dormer JP, Cooper C, Mellon JK, Barwell JG, Hollox EJ.

BJU Int. 2016 Apr;117(4):686-96. doi: 10.1111/bju.13184. Epub 2015 Jul 29.

9.

Circulating plasma microRNAs as a screening method for detection of colorectal adenomas.

Verma AM, Patel M, Aslam MI, Jameson J, Pringle JH, Wurm P, Singh B.

Lancet. 2015 Feb 26;385 Suppl 1:S100. doi: 10.1016/S0140-6736(15)60415-9.

PMID:
26312830
10.

Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma.

Moore DA, Saldanha G, Ehdode A, Mughal MZ, Potter L, Dyall L, Pringle JH.

J Mol Diagn. 2015 Sep;17(5):616-22. doi: 10.1016/j.jmoldx.2015.05.001. Epub 2015 Jun 29.

PMID:
26134170
11.

Resistance to HSP90 inhibition involving loss of MCL1 addiction.

Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M, MacFarlane M, Fennell DA.

Oncogene. 2016 Mar 24;35(12):1483-92. doi: 10.1038/onc.2015.213. Epub 2015 Jun 22.

12.

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.

Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J, Coombes RC, Ali S, Shaw JA.

Clin Chem. 2015 Jul;61(7):974-82. doi: 10.1373/clinchem.2015.238717. Epub 2015 May 15.

13.

Identification of high-risk Dukes B colorectal cancer by microRNA expression profiling: a preliminary study.

Aslam MI, Venkatesh J, Jameson JS, West K, Pringle JH, Singh B.

Colorectal Dis. 2015 Jul;17(7):578-88. doi: 10.1111/codi.12886.

PMID:
25557290
14.

MicroRNAs associated with initiation and progression of colonic polyp: a feasibility study.

Aslam MI, Hussein S, West K, Singh B, Jameson JS, Pringle JH.

Int J Surg. 2015 Jan;13:272-279. doi: 10.1016/j.ijsu.2014.12.009. Epub 2014 Dec 11.

15.

Plasticity of melanoma and EMT-TF reprogramming.

Tulchinsky E, Pringle JH, Caramel J, Ansieau S.

Oncotarget. 2014 Jan 15;5(1):1-2. No abstract available.

16.

Influence of plasma processing on recovery and analysis of circulating nucleic acids.

Page K, Guttery DS, Zahra N, Primrose L, Elshaw SR, Pringle JH, Blighe K, Marchese SD, Hills A, Woodley L, Stebbing J, Coombes RC, Shaw JA.

PLoS One. 2013 Oct 18;8(10):e77963. doi: 10.1371/journal.pone.0077963. eCollection 2013.

17.

A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.

Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E.

Cancer Cell. 2013 Oct 14;24(4):466-80. doi: 10.1016/j.ccr.2013.08.018. Epub 2013 Sep 26.

18.

Accurate detection of copy number changes in DNA extracted from formalin-fixed, paraffin-embedded melanoma tissue using duplex ratio tests.

Moore DA, Saldanha G, Ehdode A, Potter L, Dyall L, Bury D, Pringle JH.

J Mol Diagn. 2013 Sep;15(5):687-94. doi: 10.1016/j.jmoldx.2013.04.008. Epub 2013 Jun 27.

PMID:
23810241
19.

Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma.

Saldanha G, Potter L, Shendge P, Osborne J, Nicholson S, Yii N, Varma S, Aslam MI, Elshaw S, Papadogeorgakis E, Pringle JH.

J Invest Dermatol. 2013 May;133(5):1381-4. doi: 10.1038/jid.2012.477. Epub 2013 Jan 10. No abstract available.

20.

MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application.

Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH.

J Transl Med. 2012 Jun 20;10:128. doi: 10.1186/1479-5876-10-128. Review.

21.

Prognostic tissue markers in melanoma.

Moore DA, Pringle JH, Saldanha GS.

Histopathology. 2012 Apr;60(5):679-89. doi: 10.1111/j.1365-2559.2011.03910.x. Epub 2011 Aug 22. Review.

PMID:
21880059
22.

Detection of copy number changes in DNA from formalin fixed paraffin embedded tissues using paralogue ratio tests.

Saldanha G, Potter L, Dyall L, Bury D, Hathiari N, Ehdode A, Hollox E, Pringle JH.

Anal Chem. 2011 May 1;83(9):3484-92. doi: 10.1021/ac200153j. Epub 2011 Mar 30.

PMID:
21449538
23.

Phenotypic characterisation of the inner and outer myometrium in normal and adenomyotic uteri.

Mehasseb MK, Bell SC, Brown L, Pringle JH, Habiba M.

Gynecol Obstet Invest. 2011;71(4):217-24. doi: 10.1159/000318205. Epub 2010 Dec 15.

PMID:
21160148
24.

Expression of tenascin-C and its isoforms in the breast.

Guttery DS, Shaw JA, Lloyd K, Pringle JH, Walker RA.

Cancer Metastasis Rev. 2010 Dec;29(4):595-606. doi: 10.1007/s10555-010-9249-9. Review.

PMID:
20814719
25.

Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA.

Breast Cancer Res. 2010;12(4):R57. doi: 10.1186/bcr2618. Epub 2010 Aug 2. Erratum in: Breast Cancer Res. 2018 Aug 1;20(1):80.

26.

Higher serum 25-hydroxy vitamin D3 levels at presentation are associated with improved survival from melanoma, but there is no evidence that later prevailing levels are protective.

Hutchinson PE, Osborne JE, Pringle JH.

J Clin Oncol. 2010 Sep 20;28(27):e492-3; author reply 494-5. doi: 10.1200/JCO.2010.29.6095. Epub 2010 Jul 12. No abstract available.

PMID:
20625133
27.

Immunohistochemical study of epithelial-myofibroblast interaction in Barrett metaplasia.

Ochicha O, Pringle JH, Mohammed AZ.

Indian J Pathol Microbiol. 2010 Apr-Jun;53(2):262-6. doi: 10.4103/0377-4929.64341.

28.

Enhanced invasion of stromal cells from adenomyosis in a three-dimensional coculture model is augmented by the presence of myocytes from affected uteri.

Mehasseb MK, Taylor AH, Pringle JH, Bell SC, Habiba M.

Fertil Steril. 2010 Dec;94(7):2547-51. doi: 10.1016/j.fertnstert.2010.04.016. Epub 2010 May 26.

PMID:
20537634
29.

A mosaic cell layer in human pregnancy.

Byrne S, Challis E, Williams JL, Pringle JH, Hennessy JM, Ockleford CD.

Placenta. 2010 May;31(5):373-9. doi: 10.1016/j.placenta.2010.02.005. Epub 2010 Mar 16.

PMID:
20236701
31.

MicroRNAs are novel biomarkers of colorectal cancer.

Aslam MI, Taylor K, Pringle JH, Jameson JS.

Br J Surg. 2009 Jul;96(7):702-10. doi: 10.1002/bjs.6628. Review.

PMID:
19526617
32.

BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.

Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L, Saldanha G.

Br J Dermatol. 2009 Aug;161(2):364-72. doi: 10.1111/j.1365-2133.2009.09181.x. Epub 2009 Apr 29.

33.

Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms.

Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL.

Breast Cancer Res. 2009;11(2):R24. doi: 10.1186/bcr2251. Epub 2009 Apr 30.

34.

Uterine adenomyosis is associated with ultrastructural features of altered contractility in the inner myometrium.

Mehasseb MK, Bell SC, Pringle JH, Habiba MA.

Fertil Steril. 2010 May 1;93(7):2130-6. doi: 10.1016/j.fertnstert.2009.01.097. Epub 2009 Mar 6.

PMID:
19268938
35.

Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo.

Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, Sieber O, Santander S, Pringle JH, Mandir N, East P, Obszynska J, Sanders S, Piazuelo E, Shaw J, Harrison R, Tomlinson IP, McDonald SA, Wright NA, Jankowski JA.

Cancer Res. 2008 Oct 1;68(19):7760-8. doi: 10.1158/0008-5472.CAN-08-0020.

36.

WNT5A expression increases during melanoma progression and correlates with outcome.

Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox RA, Fletcher A, Saldanha GS.

Clin Cancer Res. 2008 Sep 15;14(18):5825-32. doi: 10.1158/1078-0432.CCR-07-5104.

37.

Understanding spitzoid tumours: new insights from molecular pathology.

Da Forno PD, Fletcher A, Pringle JH, Saldanha GS.

Br J Dermatol. 2008 Jan;158(1):4-14. Epub 2007 Oct 4. Review.

PMID:
17916202
38.

In silico analysis of the 5' region of the Vitamin D receptor gene: functional implications of evolutionary conservation.

Halsall JA, Osborne JE, Hutchinson PE, Pringle JH.

J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):352-6. Epub 2007 Jan 19.

PMID:
17240138
39.

Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition.

Mejlvang J, Kriajevska M, Berditchevski F, Bronstein I, Lukanidin EM, Pringle JH, Mellon JK, Tulchinsky EM.

Exp Cell Res. 2007 Jan 15;313(2):380-93. Epub 2006 Oct 26.

PMID:
17141758
40.

Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

Saldanha G, Potter L, Daforno P, Pringle JH.

Clin Cancer Res. 2006 Aug 1;12(15):4499-505.

41.

Trimegestone differentially modulates the expression of matrix metalloproteinases in the endometrial stromal cell.

Wahab M, Taylor AH, Pringle JH, Thompson J, Al-Azzawi F.

Mol Hum Reprod. 2006 Mar;12(3):157-67. Epub 2006 Mar 23.

PMID:
16556677
42.

Patterns of expression of Bax, Bcl-2 and Bcl-x(L) in the implantation site in rat during pregnancy.

Correia-da-Silva G, Bell SC, Pringle JH, Teixeira NA.

Placenta. 2005 Nov;26(10):796-806.

PMID:
16226130
43.
45.

The development and characterization of an in vitro model of psoriasis.

Barker CL, McHale MT, Gillies AK, Waller J, Pearce DM, Osborne J, Hutchinson PE, Smith GM, Pringle JH.

J Invest Dermatol. 2004 Nov;123(5):892-901.

46.

High BRAF mutation frequency does not characterize all melanocytic tumor types.

Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH.

Int J Cancer. 2004 Sep 20;111(5):705-10.

47.
48.

Patterns of uterine cellular proliferation and apoptosis in the implantation site of the rat during pregnancy.

Correia-da-Silva G, Bell SC, Pringle JH, Teixeira NA.

Placenta. 2004 Jul;25(6):538-47.

PMID:
15135237
50.

Nuclear immunostaining in rat neuronal cells using two anti-Kir2.2 ion channel polyclonal antibodies.

Stonehouse AH, Grubb BD, Pringle JH, Norman RI, Stanfield PR, Brammar WJ.

J Mol Neurosci. 2003 Apr;20(2):189-94.

PMID:
12794312

Supplemental Content

Loading ...
Support Center